# A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

> **NCT04775485** · PHASE2 · RECRUITING · sponsor: **Day One Biopharmaceuticals, Inc.** · enrollment: 141 (estimated)

## Conditions studied

- Low-grade Glioma
- Advanced Solid Tumor

## Interventions

- **DRUG:** Tovorafenib

## Key facts

- **NCT ID:** NCT04775485
- **Lead sponsor:** Day One Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-22
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775485, "A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04775485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*